Background
==========

The thalidomide catastrophe around 1960 and additional experiences such as serious adverse drug reactions to high oestrogen oral contraceptives in the 1960s were probably the main reasons for the increasingly stringent requirements set to document development safety and the establishment of spontaneous reporting systems \[[@B1],[@B2]\]. Over the years, the repeated occurrence of unexpected, serious adverse drug reactions (ADRs) has attracted wide professional and public attention, with the result that doubt has been cast on the effectiveness and quality of drug safety surveillance systems. The COX-2 scandal resulting in worldwide withdrawal of Vioxx^®^(rofecoxib) from the market in 2004 is a recent example of an ADR case that emerged unexpectedly and took the world by surprise \[[@B3]\]. Several other ADR cases have been discovered after marketing; well known are fenfluramine and the risk of pulmonal hypertension, vigabatrine and visual field defects and tolcapone and the risk of liver toxicity \[[@B4]-[@B6]\]. The repeated occurrence of serious ADR cases after medicines have been released on the market questions the extent to which existing systems and methods for predicting ADRs are effective \[[@B7]\]. Information about the ADR profile of a new medicine appears from observations made during the clinical development process \[[@B8],[@B9]\]. The gold standard for the design of these clinical trials is the randomised controlled clinical trial (RCCT) \[[@B8],[@B9]\]. The RCCT was designed to measure efficacy rather than ADRs as outcome. The design of the RCCT as hypothesis testing in itself sets narrow limits for the detection of information about serious and unexpected ADRs due to the short treatment period, the relatively small number of carefully selected participants in the trial, fixed drug doses, and hospital settings that do not reflect the conditions under which the medicines are used after marketing \[[@B8],[@B9]\]. Data on well-recognised, easily detectable ADRs may potentially be observed in RCCTs, but unknown, rare or long-term adverse effects are seldom detected in these trials due to the limitations of the RCCT. Detection of unknown or rare ADRs may include other pharmacovigilance designs, e.g. the spontaneous reporting systems, cohort or case-control studies \[[@B1],[@B10]-[@B12]\]. This article aims to review ADRs reported by available ADR signal detection approaches and to explore which information about new and unexpected ADRs these approaches have detected.

Methods
=======

We selected three different therapeutic groups of medicines for review. The groups were characterised by different:

a. Therapeutic groups
---------------------

• Antibiotics for systemic use

• Non-steroidal anti-inflammatory drugs (NSAIDs)

• Selective serotonin re-uptake inhibitors (SSRIs)

b. Market launch
----------------

Antibiotics were first marketed in the 1940s and NSAIDs in the 1960s, while SSRIs were not launched until the middle of the 1980s (internal documents, The Danish Medicines Agency).

c. ADR profiles
---------------

The therapeutic categories present different ADR profiles due to their specific pharmacological characteristics and functions.

Literature search
-----------------

Studies were identified through Medline (from 1966) and Embase (from 1989) using the following MESH terms: serotonin re-uptake inhibitors, anti-inflammatory agents, non-steroidal, anti-bacterial agents, adverse drug reaction reporting systems, pharmacoepidemiology and the key words: adverse drug reactions and information in combination. The literature search was conducted in July 2007 without language restriction. Studies written in non-European languages were later excluded. To be considered relevant for this review, articles had to be empirical in origin and focus on signal detection. Titles and abstracts of the search results were screened and relevant articles identified. The reference lists of included publications were hand-searched for possible additional relevant studies. Non peer-reviewed articles or unpublished observations were not considered. A flow chart of the study selection process for the therapeutic cases is illustrated in figure [1](#F1){ref-type="fig"}.

![**Flow chart of the study selection process for the cases**.](1472-6904-9-4-1){#F1}

Characteristics of the included studies
---------------------------------------

We developed a taxonomy inspired by general guidelines for pharmacoepidemiological research to analyse the studies systematically \[[@B13]\]. The taxonomy covers the following characteristics: publication year, design, method, explored medicine and adverse drug reactions, geographic setting, sampling period, sample size, outcome measures and results. We extracted and compared the results of published empirical studies in which various signal detection methods were used. Extracted information was entered into data sheets, one for each article. Data were extracted and handled by the first author and checked by the second author.

Analyses
--------

For each of the three selected therapeutic groups, we analysed the time of publication, the strengths of the evidence in the different approaches, reported ADRs and whether the studies had produced new information about ADRs compared to the information available at the time of marketing.

### Classification of the tested/detected ADRs

For each included literature reference, the ADRs tested or detected via the various signal detection approaches were classified according to Rawlins\' classification system \[[@B14]\]. An overview of the classification system is shown in table [1](#T1){ref-type="table"}. The reported/detected ADRs were also classified according to System Organ Classes in keeping with MedDRA terminology \[[@B13]\].

###### 

Rawlins\' classification system of ADRs

  Type   Definition
  ------ ------------------------------------------------------------------------
  A      Dose-dependent ADRs related to the pharmacological effect of the drug:
          • Increased pharmacological effect
          • ADRs that occur secondarily to the desired pharmacological effect
          • ADRs due to other well known pharmacological effects
         
  B      Sensitivity reactions -- not dose-dependent
          • Allergic reactions
          • Idiosyncratic reaction
         
  C      Long-term ADRs
          • Carcinogines
          • Teratogenes
          • Chronic organ damage
         
  D      Drug-drug interactions
          • Pharmacodynamic
          • Pharmacokinetic
          • Non-classifiable

### Classification of applied approaches

The explored approaches were classified into analytical or observational approaches according to Strom\'s definitions \[[@B13]\]. Case-control and cohort studies are classified as analytical methods, while spontaneous reporting, case series/case reports and PEM studies are observational \[[@B13]\].

### Time of publication

For each therapeutic group, we analysed whether there was a connection between time of publication and the applied study design.

### Strength of evidence

Evidence-based medicine operates with an evidence hierarchy for evaluating the quality of the various study designs used for therapeutic studies \[[@B13]\]. At the top of this hierarchy are the meta-analyses (level 1), followed by RCCTs at the second level and other controlled trials at the third level. Cohort studies are placed at the fourth level, followed by case-control studies at the fifth level. At the bottom of the evidence hierarchy are cross-sectional surveys (level 6) and anecdotal case reports (level 7) \[[@B13]\].

Results
=======

The literature search identified 327 potentially relevant references for all three therapeutic groups, 149 of which were selected from the titles and abstracts and further screened for relevance. Eventually 79 references were included in this analysis. A flow chart of the selection and exclusion process is illustrated in figure [1](#F1){ref-type="fig"}. The included studies were distributed on the three therapeutic cases as follows: antibiotics: 23 studies; NSAID: 35 studies; SSRI: 20 studies. One reference was not accessible.

ADR detection approaches applied
--------------------------------

Table [2](#T2){ref-type="table"} provides an overview of the categorisation of the designs used in the included studies and their rank in the evidence hierarchy \[[@B13]\]. As the table indicates, the majority of the included studies dealt with analyses of data reported in Prescription Event Monitoring (PEM) programs and ADRs reported to national ADR databases, approaches ranking at levels six and seven in the evidence hierarchy.

###### 

The analysed studies categorised by study design

  ---------------------------------------------------------------------------------------------------------------------------
  **Study design**              **Rank in evidence hierarchy**                     **Therapeutic**\               
                                                                                   **cases**                      
  ----------------------------- -------------------------------- ----------------- ------------------ ----------- -----------
                                                                 **Antibiotics**   **NSAIDs**         **SSRIs**   **Total**

                                                                                                                  

  Cohort                        4                                5                 4                  1           10

                                                                                                                  

  Case control                  5                                2                 3                  2           8

                                                                                                                  

  PEM\*                         6                                2                 9                  4           15

                                                                                                                  

  National ADR databases        7                                7                 14                 11          32

                                                                                                                  

  Case series                   7                                2                 3                  1           6

                                                                                                                  

  Case reports                  7                                5                 2                  1           8

                                                                                                                  

  **Total number of studies**                                    **23**            **36**             **20**      **79**
  ---------------------------------------------------------------------------------------------------------------------------

\*Prescription Event Monitoring Studies

Study characteristics
---------------------

Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} display the characteristics and descriptions of the analysed studies for each therapeutic case \[[@B15]-[@B92]\]. The tables show that the studies primarily dealt with analyses of ADRs of the type A and B, and to a lesser extent C and D. The evidence level of ADRs varied widely; some of the ADRs were documented in both the analytical and observational studies, others in only one of the designs.

###### 

Characteristics of studies of the occurrence of ADRs related to antibiotics use

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                 **Setting**   **Medicines**      **ADRs**                              **Sampling period**   **Sample size**             **Outcome**\                        **Results**\                             **Type of ADRs**
                                                                                                                                                         **measures**                        **(95% CI)**                             
  ----------------------------- ------------- ------------------ ------------------------------------- --------------------- --------------------------- ----------------------------------- ---------------------------------------- ------------------
  **Case control studies**                                                                                                                                                                                                            

                                                                                                                                                                                                                                      

  Czeizel 1999 \[[@B15]\]       HU            Erythromycin       Teratology                            1980--1996            113 cases/38,151 controls   OR                                  1.1; 0.5--2.3                            C

                                                                                                                                                                                                                                      

  Seeger 2006 \[[@B16]\]                      Fluoroquinolones   Achilles tendon rupture               1997--2001            947 cases/\                 OR                                  1.2; 0.9--1.7                            B
                                                                                                                             18,940 controls                                                                                          

                                                                                                                                                                                                                                      

  **Cohort studies**                                                                                                                                                                                                                  

                                                                                                                                                                                                                                      

  Chysky 1991\[[@B17]\]         DE            Ciprofloxacin      Not specified                         44 days               634 patients                \% ADRs                             Different categories reported            A/B

                                                                                                                                                                                                                                      

  Derby 1993 \[[@B18]\]         AU            Flucloxacillin     Cholestatic hepatitis                 45 days               132,087 patients            PRR/100,000 users                   7.6; 3.5--13.9                           B

                                                                                                                                                                                                                                      

  Jick 1994 \[[@B19]\]          AU            Flucloxacillin     Cholestatic hepatitis                 1991--1992            77,552 patients             PRR/\                               6.5; 2.7--15.1                           B
                                                                                                                                                         100,000 users                                                                

                                                                                                                                                                                                                                      

  Derby 1993b \[[@B20]\]        AU            Erythromycin       Cholestatic hepatitis                 \-                    366,064 patients            PRR/100,000 users                   3,6; 1.9--6.1                            B

                                                                                                                                                                                                                                      

  Heymann 2007 \[[@B21]\]       Israel        Penicillins        Pemphigus                             1997--2001            150,000 patients            OR                                  2.03; 1.56--2.64                         B

                                                                                                                                                                                                                                      

  **PEM**                                                                                                                                                                                                                             

                                                                                                                                                                                                                                      

  Clark 2001 \[[@B22]\]         UK            Fluoroquinolones   Cardiovascular events                 1988--1991            36,410 patients             CRR (crude relative risk)           Atrial fibrillation: 1.0; 0.02 -- 8.92   B

                                                                                                                                                                                                                                      

  Inman1994 \[[@B23]\]          UK            Fluconazole        All                                   1988--1989            15,015 patients             Frequencies                         Different categories reported            A

                                                                                                                                                                                                                                      

  **National ADR databases**                                                                                                                                                                                                          

                                                                                                                                                                                                                                      

  Polimeni 2006 \[[@B49]\]      Sicilian      Antibacterials     All                                   1998--2002            1585 cases                  ADRs                                Different categories reported            A

                                                                                                                                                                                                                                      

  Sachs 2006 \[[@B24]\]         DE            Fluoroquinolones   Anaphylaxis                           1993--2004            204 cases                   PRR \> 2                            Moxifloxacin: 2.1;\                      B
                                                                                                                                                                                             Ofloxacin: 2.3\                          
                                                                                                                                                                                             Ciprofloxacin: 2.3\                      
                                                                                                                                                                                             Levofloxacin: 2.0                        

                                                                                                                                                                                                                                      

  Fleisch 2000 \[[@B25]\]       CH            Levofloxacin       Tendinopathy                          1986--1999            19 cases/460 non-cases      Reporting rate                      Different categories reported            B

                                                                                                                                                                                                                                      

  Leone 2003 \[[@B26]\]         IT            Fluroquinolones    Not specified                         1999--2001            432 cases/\                 Reporting rate                      Different categories reported            A
                                                                                                                             10,011 non cases                                                                                         

                                                                                                                                                                                                                                      

  Pierfitte 2000 \[[@B27]\]     FR            Sparfloxacin       Phototoxicity                         1994--1996            371 cases                   RtR/1000 patients                   0.4                                      B

                                                                                                                                                                                                                                      

  Frothingham 2005 \[[@B28]\]   US            Gatifloxacin       Glucose homeostatis abnormalities     1997--2003            453 cases/\                 Reporting rate/10^7^prescriptions   477                                      A
                                                                                                                             1427 non cases                                                                                           

                                                                                                                                                                                                                                      

  Hedenmalm 1996 \[[@B29]\]     SE            Fluorquinolones    Sensory disturbances                  1965--1993            37 cases                    ADRs                                Different categories reported            A

                                                                                                                                                                                                                                      

  **Case series**                                                                                                                                                                                                                     

                                                                                                                                                                                                                                      

  Abouesh 2002 \[[@B30]\]       \-            Fluorquinolones\   Mania                                 \-                    102 cases                   Case review                         Case review                              B
                                              Macrolides                                                                                                                                                                              

                                                                                                                                                                                                                                      

  Smith 2005 \[[@B31]\]         \-            Doxycycline\       ADRs                                  1966--2003            130 cases                   Incidences                          Doxycycline: 0--61%\                     A
                                              Minocycline                                                                                                                                    Minocycline: 11.7 -- 83.3%               

                                                                                                                                                                                                                                      

  **Case reports**                                                                                                                                                                                                                    

                                                                                                                                                                                                                                      

  Hällgren 2003 \[[@B32]\]      \-            Ciprofloxacin      Steven-Johnson syndrome               1988--2000            8 cases                     IC pr. 100,000 patients             0.045                                    B

                                                                                                                                                                                                                                      

  Warner 2000 \[[@B33]\]        \-            Clarithromycin     Acute Psychotic Stress                \-                    1 case                      Causality assessment                Possible                                 A

                                                                                                                                                                                                                                      

  ADRAC 1992 \[[@B34]\]         \-            Flucloxacillin     Cholestatic hepatitis                 \-                    1 case                      Case review                         Case review                              B

                                                                                                                                                                                                                                      

  Greco 1997 \[[@B35]\]         \-            Clarithromycin     Glossitis, stomatitis, black tongue   \-                    1 case                      Case review                         Case review                              B

                                                                                                                                                                                                                                      

  Björnsson 1996 \[[@B36]\]     \-            Doxycycline        Liver reactions                       1966--1995            23 cases                    Causality assessment                Likely (n = 3)\                          B
                                                                                                                                                                                             Possible (n = 8)                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of studies of the occurrence of ADRs related to NSAID use

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                    **Setting**   **Medicines**       **ADRs**                                **Sampling period**   **Sample size**                     **Outcome measures**                          **Results**\                                            **Type of ADRs**
                                                                                                                                                                                                                     **(95%CI)**                                             
  -------------------------------- ------------- ------------------- --------------------------------------- --------------------- ----------------------------------- --------------------------------------------- ------------------------------------------------------- ------------------
  **Case control**\                                                                                                                                                                                                                                                          
  **studies**                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                             

  Hernandez-Diaz 2001\[[@B37]\]    UK            NSAIDs              Gastrointestinal events                 1993--1998            2,105 cases/\                       OR                                            1.8; 1.3 -- 2.4.                                        A
                                                                                                                                   11,500 controls                                                                                                                           

                                                                                                                                                                                                                                                                             

  Mockenhaupt 2003 \[[@B38]\]      DE/US         NSAIDs              Steven-Johnson syndrome                 1989--1995            245 cases/\                         PRR                                           34, 95; 11--105                                         B
                                                                                                                                   1147 controls                                                                                                                             

                                                                                                                                                                                                                                                                             

  Lacroix 2004 \[[@B39]\]          FR            NSAIDs              Liver injury                            1998--2000            88 cases/\                          OR                                            Women:\                                                 B
                                                                                                                                   178 controls                                                                      6.49; 1.67--25.16\                                      
                                                                                                                                                                                                                     Men: 1.06; 0.36--3.12                                   

                                                                                                                                                                                                                                                                             

  **Cohort studies**                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                             

  Lipworth 2004 \[[@B40]\]         DK            Ibuprofen           Mortality                               1989--1995            113,538\                            SMR (standard mortality rate)                 1.21; 1.19--1.24                                        A/B
                                                                                                                                   patients                                                                                                                                  

                                                                                                                                                                                                                                                                             

  Ashworth 2004 \[[@B41]\]         CA            Diclofenac\         Mortality                               1991--1994            18,424 patients                     OR                                            Arthrotec: 1.4; 0.9--2.1.\                              A/B
                                                 Naproxen\                                                                                                                                                           Diclofenac: 2.0; 1.3--3.1.\                             
                                                 Arthrotec                                                                                                                                                           Naproxen: 3.0; 1.9--4.6                                 

                                                                                                                                                                                                                                                                             

  Morant 2004 \[[@B42]\]           UK            NSAIDs              Gastrointestinal haemorrhage            1987--2001            628000 patient year                 PRR                                           0.84; 0.60 -- 1.17                                      A

                                                                                                                                                                                                                                                                             

  Martin 2000 \[[@B43]\]           UK            Meloxicam           Gastrointestinal events                 1996--1997            19,087 patients                     Events/\                                      Dyspepsia: 28.3\                                        A + B
                                                                                                                                                                       1000 patient-months of exposure               Gastrointestinal haemorrhage: 0.4                       

                                                                                                                                                                                                                                                                             

  **National ADR databases**                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                             

  Lugardon 2004 \[[@B44]\]         FR            COX-2 inhibitors    Oeso-gastro-duodenal events:            2000--2002            505 cases/\                         OR                                            14.9; 9.3--23.7                                         A
                                                                                                                                   2,525 non-cases                                                                                                                           

                                                                                                                                                                                                                                                                             

  Durrieu 2005 \[[@B45]\]          FR            COX-2 inhibitors    Arterial hypertension                   2000--2003            34 cases                            OR                                            3.3; 1.6--6.9.                                          A

                                                                                                                                                                                                                                                                             

  Clinard 2004 \[[@B46]\]          FR            NSAIDs              Excess risk of adverse drug reactions   1995--1999            3983 cases/\                        OR                                            Different categories reported                           B
                                                                                                                                   54,583 non- cases                                                                                                                         

                                                                                                                                                                                                                                                                             

  Brinker 2004 \[[@B47]\]          US            COX-2 inhibitors    Hypertension                            \< 2002               34 cases                            Reporting rate/10^6^person years              Rofecoxib: 5.0\                                         A
                                                                                                                                                                                                                     Celecoxib: 1.3                                          

                                                                                                                                                                                                                                                                             

  La Grenade 2005 \[[@B48]\]       US            COX-2 inhibitors\   Steven-Johnson syndrome\                \< 2004               123 cases                           Reporting rate/10^6^person years              Valdecoxib: 49\                                         B
                                                 Meloxicam           Toxic Epidermal Necrolysis                                                                                                                      Celecoxib: 6\                                           
                                                                                                                                                                                                                     Rofecoxib: 3                                            

                                                                                                                                                                                                                                                                             

  Polimeni 2006 \[[@B49]\]         Sicilian      NSAIDs              All                                     1998--2002            1585 cases                          PRR                                           Hepatitis: 14.20\                                       B
                                                                                                                                                                                                                     Vasculitis: 7.72\                                       
                                                                                                                                                                                                                     Hypertension: 15.40                                     

                                                                                                                                                                                                                                                                             

  Conforti 2001 \[[@B50]\]         IT            NSAIDs              Gastrointestinal events                 1996--1999            705 cases/\                         \% ADRs                                       Nimesulid: 10.4\                                        A
                                                                                                                                   10,608 non cases                                                                  Diclofenac: 21.2\                                       
                                                                                                                                                                                                                     Ketoprofen: 1.7\                                        
                                                                                                                                                                                                                     Piroxicam: 18.6                                         

                                                                                                                                                                                                                                                                             

  Ahmad 2002 \[[@B51]\]            US            COX-2 inhibitors    Renal failure                           1969--2000            Celecoxib: 122 cases\               Case review                                   Case review                                             A
                                                                                                                                   Rofecoxib: 142 cases                                                                                                                      

                                                                                                                                                                                                                                                                             

  Puijenbroek 2000 \[[@B52]\]      NL            NSAIDs\             Drug interactions                       1990--1999            305 cases/\                         OR                                            OR: 2.0, 1.1--3.7                                       D
                                                 Diuretics                                                                         9517 non cases                                                                                                                            

                                                                                                                                                                                                                                                                             

  Lapeyre-Mestre 2004 \[[@B53]\]   FR/ES         NSAIDs              Hepatic events                          1982--2001            29,486 cases                        OR                                            Different OR calculated for NSAIDs.                     B

                                                                                                                                                                                                                                                                             

  Leone 1999 \[[@B54]\]            IT            Nimesulide          Renal impairment                        1988--1997            11cases/\                           Causality assessment                          Possible (n = 6)\                                       A
                                                                                                                                   7438 non cases                                                                    Probable (n = 4)\                                       
                                                                                                                                                                                                                     Certain (n = 1)                                         

                                                                                                                                                                                                                                                                             

  Brown 1998 \[[@B55]\]            UK            Tiaprofenic acid    Cystitis                                1981--1996            221 cases/\                         ADRs/10^5^prescriptions                       1991: 4.2\                                              B
                                                                                                                                   1327 non cases                                                                    1992: 5.9\                                              
                                                                                                                                                                                                                     1993: 4.2\                                              
                                                                                                                                                                                                                     1994: 34.4\                                             
                                                                                                                                                                                                                     1995: 18.5\                                             
                                                                                                                                                                                                                     1996: 6.5                                               

                                                                                                                                                                                                                                                                             

  Verrico 2003 \[[@B56]\]          US            COX2-inhibitors     Not specified                           1999--2002            24 cases                            Causality assessment                          Possible (n = 29)\                                      A
                                                                                                                                                                                                                     Probable (n = 16)                                       

                                                                                                                                                                                                                                                                             

  Kahn 1997 \[[@B57]\]             US            NSAIDs              Necrotizing soft tissue infections      1969--1995            33 cases                            Case review                                   N = 26                                                  C

                                                                                                                                                                                                                                                                             

  **PEM**                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                             

  Layton 2004a \[[@B58]\]          UK            Celecoxib           Not specified                           2000                  17,458 patients                     IDs (event incidence densitites)              Dyspepsia = 25.4\                                       A + B
                                                                                                                                                                                                                     Abdominal pain = 10.6                                   

                                                                                                                                                                                                                                                                             

  Layton 2003b \[[@B59]\]          UK            Celecoxib\          Not specified                           1996--1997            34,355 patients                     PRR                                           Different categories reported                           A
                                                 Meloxicam                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                             

  Layton 2003c \[[@B60]\]          UK            Rofecoxib           Not specified                           2000                  15,268 patients                     Event rate pr. 1000 patient months exposure   76 upper GI bleedings and 101 thromboembolic events     A + B

                                                                                                                                                                                                                                                                             

  Layton 2004d \[[@B61]\]          UK            Rofecoxib           Exacerbation of colitis                 1999                  15,268 patients                     IRR                                           5.8; 2.7--11.3                                          A

                                                                                                                                                                                                                                                                             

  Kasliwal 2005 \[[@B62]\]         UK            COX-2 inhibitors    Gastrointestinal +\                     1999--2000            32,726 patients                     PRR                                           GI: 1.21; 1.09 -- 1.36.\                                A + B
                                                                     thromboembolic events                                                                                                                           Thromboembolic: 1.04; 0.50 -- 2.17.                     

                                                                                                                                                                                                                                                                             

  Layton 2003e \[[@B63]\]          UK            Rofecoxib\          Thromboembolic events                   1996--1997            34,355 patients                     PRR                                           1.68; 1.15 -- 2.46.                                     A
                                                 Meloxicam                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                             

  Layton 2003f \[[@B64]\]          UK            Rofecoxib\          Upper GI events                         1996--1997            34,355 patients                     IR                                            0.71; 0.65 -- 0.79.                                     A
                                                 Meloxicam                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                             

  Layton 2006g \[[@B65]\]          UK            COX-2 inhibitors    Serious skin reactions                  1999--2000/           52,644 patients                     IR/1000 patient-months                        IR: 0.019                                               B

                                                                                                                                                                                                                                                                             

  Layton 2003h \[[@B66]\]          UK            Celecoxib\          Gastrointestinal events                 1996--1997            36,545 patients                     PRR                                           0.77; 0.69 -- 0.85.                                     A
                                                 Meloxicam                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                             

  **Case series**                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                             

  Onder 2004 \[[@B67]\]            \-            NSAIDs              Psychiatric ADRs                        1965--2003            27 reports with data on 453 cases   Risk factors                                  Age, psychiatric disorders, parturients                 B

                                                                                                                                                                                                                                                                             

  Fraunfelder 2006 \[[@B68]\]      \-            NSAIDs              Ocular ADRs                             \-                    569 cases                           Reported ADRs                                 Blurred vision, conjunctivitis, visual hallucinations   B

                                                                                                                                                                                                                                                                             

  Zimer 2007 \[[@B69]\]            DE            Valdecoxib          Cutaneous adverse reactions             2002--2005            5 cases                             Case review                                   Erythematous, facial edema, dyspnea                     B

                                                                                                                                                                                                                                                                             

  **Case reports**                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                             

  Hunter 1999 \[[@B70]\]           \-            Bromfenac           Hepatic Failure                         \-                    1 case                              Causality assessment                          Related                                                 B

                                                                                                                                                                                                                                                                             

  ADRAC 1998 \[[@B71]\]            \-            Diclofenac\         Closure of fetal ductus arterious       \-                    3 cases                             Case review                                   Case review                                             C
                                                 Indomethacin\                                                                                                                                                                                                               
                                                 Mefenamic acid                                                                                                                                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Studies of the occurrence of ADRs related to SSRI use

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                  **Setting**   **Medicines**   **ADRs**                               **Sampling period**   **Sample size**              **Outcome measures**        **Results**\                            **Type of ADRs**
                                                                                                                                                                                     **(95% CI)**                            
  ------------------------------ ------------- --------------- -------------------------------------- --------------------- ---------------------------- --------------------------- --------------------------------------- ------------------
  **Case-control studies**                                                                                                                                                                                                   

                                                                                                                                                                                                                             

  Schillevoort 2002 \[[@B72]\]   NL            SSRIs           Extrapyramidal\                        1985--1999            41cases/1,264 controls       OR                          2.2; 1.2--3.9                           A
                                                               Syndromes (EPS)                                                                                                                                               

                                                                                                                                                                                                                             

  Movig 2002 \[[@B73]\]          NL            SSRIs           Hyponatraemia                          1990--1998            203 cases/608 controls       OR                          3.96; 1.33 -- 11.83                     A

                                                                                                                                                                                                                             

  **Cohort study**                                                                                                                                                                                                           

                                                                                                                                                                                                                             

  Bell 2006 \[[@B74]\]           US            Fluoxetine      Testosterone levels                    \-                    14 patients                  Testosterone level          No changes                              B

                                                                                                                                                                                                                             

  **National ADR databases**                                                                                                                                                                                                 

                                                                                                                                                                                                                             

  Trenque 2002 \[[@B75]\]        FR            SSRIs           Withdrawal syndrome                    \< 2000               60 cases/166,327 non cases   OR                          5.05, 3.81--6.68.                       A

                                                                                                                                                                                                                             

  Gony 2003 76\]                 FR            SSRIs           Extrapyramidal\                        1995--2000            9 cases                      OR                          2.18; 0.47--11.35                       A
                                                               Symptoms                                                                                                                                                      

                                                                                                                                                                                                                             

  Hedenmalm 2006 \[[@B77]\]      SE            SSRIs           Alopecia                               \< 2004               27 cases                     IC                          Sertraline = 1.63, 0.85--2.41\          B
                                                                                                                                                                                     Citalopram = 1.22, 0.97--1.47           

                                                                                                                                                                                                                             

  Goldstein 1997 \[[@B78]\]      \-            Fluoxetine      First-trimester exposure on newborns   \< 1996               796 cases                    Rate %                      5.0                                     C

                                                                                                                                                                                                                             

  Spigset 2003 \[[@B79]\]        SE            Nefazodone      Hepatic injury                         \< 2002               27,542 cases/\               IC                          0.42, 0.12--0.72                        B
                                                                                                                            2830764 non cases                                                                                

                                                                                                                                                                                                                             

  Khan 2003 \[[@B80]\]           US            SSRIs           Suicide                                1985--2000            77 cases/48,277\             Suicide rate                0.59, 0.31 -- 0.87                      A
                                                                                                                            non cases                                                                                        

                                                                                                                                                                                                                             

  Egberts 1997 \[[@B81]\]        NL            SSRIs           Non-puerperal lactation                1986--1996            38cases/14,439 non cases     OR                          2.7; 6.4--25.4                          A

                                                                                                                                                                                                                             

  Kvande 2001 \[[@B82]\]         NO            SSRIs           Pancreatitis                           \< 2000               160 cases                    No. of cases                160 cases                               B

                                                                                                                                                                                                                             

  Stahl 1997 \[[@B83]\]          SE            SSRIs           Withdrawal reactions                   \< 1995               49, 393 cases                Number of reports/10^6^/\   Paroxetine = 1.9\                       A
                                                                                                                                                         DDD                         Sertraline = 2.1\                       
                                                                                                                                                                                     Fluoxetine = 0.48                       

                                                                                                                                                                                                                             

  Spigset 1999 \[[@B84]\]        SE            SSRIs           Not specified                          1965--1997            1202 cases                   ADRs                        Different categories reported           A + B

                                                                                                                                                                                                                             

  Sanz 2005 \[[@B85]\]           SE            SSRIs           Neonatal withdrawal syndrome           1968--2002            102 cases                    IC                          Paroxetine = 4.07\                      C
                                                                                                                                                                                     Sertraline = 1.20\                      
                                                                                                                                                                                     Citalopram = 1.92\                      
                                                                                                                                                                                     Fluoxetin = 1.07                        

                                                                                                                                                                                                                             

  **PEM**                                                                                                                                                                                                                    

                                                                                                                                                                                                                             

  Price 1996 \[[@B86]\]          UK            SSRIs           Withdrawal reactions                   1987--1992            50,150 patients              Reports/\                   Paroxetine = 0.3\                       A
                                                                                                                                                         1000 prescriptions          Sertraline = 0.03\                      
                                                                                                                                                                                     Fluvoxamine = 0.03\                     
                                                                                                                                                                                     Fluoxetine = 0.002                      

                                                                                                                                                                                                                             

  Layton 2001 \[[@B87]\]         UK            SSRIs           Abnormal bleeding                      1986--1998            135,754 patients             PRR                         Day 1--30 = 1.38\                       A
                                                                                                                                                                                     Month 2--6 = 1.17                       

                                                                                                                                                                                                                             

  Edwards 1994 \[[@B88]\]        UK            Fluvoxamine     All                                    1987--1988            10,401 patients              Incidences                                                          A

                                                                                                                                                                                                                             

  MacKay 1997 \[[@B89]\]         UK            SSRIs           All                                    1988--1991            56,145 patients                                          Nausea, vomiting, withdrawal symptoms   

                                                                                                                                                                                                                             

  **Case series**                                                                                                                                                                                                            

                                                                                                                                                                                                                             

  de Abajo 2006 \[[@B90]\]       \-            SSRIs\          Bleeding Disorders                     1988--2003            1,651 cases/\                PRR                         3.0, 2.1--4.4                           A
                                               Venlafaxine                                                                  10,000 controls                                                                                  

                                                                                                                                                                                                                             

  Gram 1999 \[[@B91]\]           DK            SSRIs           Bleeding\                              \-                    8 cases                      \-                          Case review                             A + B
                                                               Thrombocytopenia                                                                                                                                              

                                                                                                                                                                                                                             

  **Case report**                                                                                                                                                                                                            

                                                                                                                                                                                                                             

  Demers 2001 \[[@B92]\]         \-            Fluvoxamine     Serotonin syndrome                     \-                    1 case                       \-                          Case review                             A
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data sources
------------

Case-control studies were carried out on data from various national registers and/or data from spontaneous ADR databases, physicians\' databases such as the General Practitioners\' database in the UK and Health Insurance Databases \[[@B15],[@B16],[@B37],[@B38],[@B72],[@B73]\]. The studies were reported in the literature from the mid-1980s to the end of the 1990s. Cohort studies analysed ADR data collected from the mid-1980s to the end of the 1990s. The cohort studies varied in size from less than 20,000 patients to between 20,000--50,000 and more than 100,000 patients \[[@B17],[@B19],[@B21],[@B40],[@B41]\]. The PEM studies were conducted in the UK at the Drug Safety Unit in Southampton, and were based on data collected from the mid-1980s to the end of the 1990s \[[@B22],[@B23],[@B58]-[@B66],[@B86]-[@B89]\]. Studies analysing spontaneously reported ADRs were conducted on large spontaneous reporting databases such as the French, American, British and the Uppsala Monitoring Centre WHO database \[[@B44]-[@B48],[@B51],[@B55]-[@B57],[@B62],[@B74]-[@B76],[@B79],[@B82],[@B83],[@B85]\].

Design and historical perspective
---------------------------------

The antibiotic studies were published from 1990 and onwards, most of them from 1995. Cohort studies were published during 1990--1994, while the PEM studies, spontaneous reporting, case reports/case series primarily were published after 1995. The majority of the NSAID studies were published after year 2000. The SSRI studies were published from 1990 to present, most of them from 1995 to 2005. Table [6](#T6){ref-type="table"} shows the distribution of the analysed studies by type of approach, therapeutic case, and time of publication. For all therapeutic cases, data were collected and the studies published a long time after the drugs were first marketed. Despite the decades of difference in market launches for the therapeutic cases, the studies are mainly published from the end of the 1990s and on. Data were collected earlier.

###### 

Number of studies categorised by number, design and time of publication

  **Year of publication**   **\< 1990**   **1991**   **1992**   **1993**   **1994**   **1995**   **1996**   **1997**   **1998**   **1999**   **2000**   **2001**   **2002**   **2003**   **2004**   **2005-**
  ------------------------- ------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----------
  **Study design**                                                                                                                                                                                  
                                                                                                                                                                                                    
  **Antibiotics**                                                                                                                                                                                   
                                                                                                                                                                                                    
  Case control studies                                                                                                            1                                                                 1
  Cohort studies                          1                     3                                                                                                                                   1
  National ADR databases                                                                         1                                           2                                1                     2
  PEM\*                                                                    1                                                                            1                                           
  Case series                                                                                                                                                      1                                1
  Case reports                                       1                                           1          1                                1                                1                     
                                                                                                                                                                                                    
  **NSAIDs**                                                                                                                                                                                        
                                                                                                                                                                                                    
  Case control studies                                                                                                                       1          1                     1          1          
  Cohort studies                                                                                                                             1                                           3          
  National ADR databases                                                                                    1          1          1          1          1          1          1          4          3
  PEM\*                                                                                                                                                                       5          2          2
  Case series                                                                                                                                                                            1          2
  Case reports                                                                                                         1          1                                                                 
                                                                                                                                                                                                    
  **SSRIs**                                                                                                                                                                                         
                                                                                                                                                                                                    
  Case control studies                                                                                                                                             2                                
  Cohort studies                                                                                                                                                                                    1
  National ADR databases                                                                                    3                     1                     1          1          3                     2
  PEM\*                                                                    1                     1          1                                           1                                           
  Case series                                                                                                                     1                                                                 1
  Case reports                                                                                                                                          1                                           

\*Prescription Event Monitoring Studies

Explored and detected ADRs
--------------------------

### Antibiotics

ADRs from newer types of antibiotics, such as fluoroquinolones, have been reported much more frequently in the literature than ADRs from the older antibiotics, such as penicillins and macrolides \[[@B15]-[@B17],[@B19],[@B20],[@B22]-[@B24],[@B26],[@B29],[@B33],[@B34],[@B36]\]. The studies explore a possible risk between the use of antibiotics and the risk of liver, cardiovascular, CNS and dermatological ADRs \[[@B18]-[@B20],[@B22],[@B24],[@B27],[@B29],[@B30],[@B32],[@B33],[@B36]\]. Three cohort studies documented a correlation between cholestatic hepatitis and the use of flucloxacillin \[[@B18]-[@B20]\]. Increased risk of palpitation from the use of norfloxacin compared to ciprofloxacin/ofloxacin was demonstrated \[[@B22]\]. Cohort studies further demonstrated a risk of pemphigus related to penicillins, liver injury related to flucloxacillin and erythromycin \[[@B18]-[@B21]\]. CNS and dermatological ADRs from treatment with antibiotics have been reported rarely and on the case report level \[[@B30],[@B32],[@B33]\]. New information about ADRs was only produced by case reports: acute psychotic stress and glossitis/black tongue \[[@B34],[@B35]\].

### NSAIDs

Studies explored the risk of gastrointestinal \[[@B37]-[@B44],[@B50]\] and dermatological ADRs as well as the development of liver and kidney toxicity which are well known ADRs associated with NSAIDs and their pharmacological characteristics\[[@B38],[@B39],[@B48],[@B51],[@B53],[@B54],[@B57],[@B65],[@B69],[@B70]\]. The studies were generated after the launch of COX-2 inhibitors in the mid-1990s. A case-control study documented increased risk of developing dermatological ADRs of the type Steven-Johnson Syndrome and toxic epidermal necrolysis as did spontaneously reported ADRs \[[@B38],[@B48]\]. A case-control study documented hepatic injury related to the use of NSAIDs, as did spontaneously reported ADRs, while renal injury and hypertension was documented in spontaneous reports and thromboembolic events in a PEM study \[[@B39],[@B45],[@B47],[@B51],[@B53],[@B54],[@B63],[@B70]\]. With the exception of case reports, the approaches used did not produce information about ADRs that had not been reported previously.

### SSRIs

Studies explored the risk of extrapyramidal symptoms, withdrawal syndromes and serotonin syndrome with the use of SSRIs, other ADRs investigated were: changes in testosterone and natrium level, alopecia, liver injury and bleeding. ADRs reported only via spontaneous reports are first-trimester exposure on newborns and neonatal withdrawal syndrome, hepatic injury and pancreatitis, suicide, non-puerperal lactation and serotonin syndrome \[[@B72]-[@B81],[@B79],[@B83],[@B85],[@B86],[@B90]-[@B92]\]. With the exception of case reports, the approaches used did not detect new ADR signals that had not been reported previously \[[@B90]-[@B92]\].

Information about ADRs reported across approaches
-------------------------------------------------

### Analytical

The approaches produced information about ADR risks compared to placebo or similar drugs as either odds ratios (OR), proportional reporting ratio (PRR) estimates, incidences (IC) and frequencies of ADRs. These parameters are built into the design and based on previous information or hypothesis. The studies were conducted on various patient populations, various medicines within the individual sub-groups, and different types of ADRs, different outcome measures, data sources and time periods. The purpose of the approaches made it possible to adjust the ADR estimate for known confounders and risk factors.

### Observational

The approaches produced information about ADRs as estimates (OR, PRR, IC) or as single observations compared to placebo/similar medicines. Case reporting was the only approach that contributed new information about new ADRs in all three therapeutic cases.

Discussion
==========

This review has several main findings:

First, analytical approaches ranging higher in the evidence hierarchy provided information about risks of already known or expected ADRs, while information about new and unknown ADRs was detected by case reports only, which range at the lowest level in the evidence hierarchy. Second, the studies primarily dealt with analyses of ADRs of type A and B, and only a few studies analysed type C and D. Third, similar approaches, both analytical and observational, were applied to all therapeutic cases. Fourth, the ADR cases provided similar results with regard to detecting new ADRs despite their connection to different time periods and organs attacked.

Methodological quality and capability of approaches
---------------------------------------------------

There is a general lack of standards in the field of ADRs, particularly because many ADRs are not detected until after marketing and the studies are based on selected patient groups, which makes it difficult to generalise the results to other patient groups. As previously argued in the literature, testing specific hypotheses in the analytical approaches makes it difficult to capture information about new and unknown ADRs \[[@B13]\]. Despite the fact that these types of studies rank high in the evidence hierarchy, the weaker design of the observational studies makes them more suitable for discovering previously undetected ADRs. Healthcare professionals have conventionally considered cohort and case-control studies to be well suited for post-marketing surveillance of ADRs, despite their lack of randomisation and lower position in the evidence hierarchy, level 4 and 5 respectively \[[@B14]\]. These studies primarily detected/analysed ADRs of type A and B and less frequently type C and D \[[@B14]\]. Thus, the approaches are not designed and therefore are not suitable for predicting new information about other ADRs that have not previously been detected or ADRs of the type C or D \[[@B14]\]. Case reports have provided data about patients, suspected ADRs, medicines involved and so on, but this information is often anecdotal in nature and collected retrospectively. However, it is interesting that despite their low rank in the evidence hierarchy, these reports provide new information about rare and previous undetected ADRs. Case reports may serve as whistleblowers, thereby initiating larger systematic analyses of patient populations or registering data to quantify the risk. A large majority of spontaneously reported ADRs are stored in databases hosted by regulatory agencies. Information about these observations is typically only released to the public in the form of press releases, insertions in product information or messages in national bulletins. If all these signals were published in the scientific literature or made public on the web pages of regulatory agencies, the number of spontaneous reports/case series would probably have been larger and added to the relative dominance of this design \[[@B93],[@B94]\]. The results confirm that spontaneous post-marketing reporting of ADRs is of great importance and that regulatory agencies must continue to encourage spontaneous reporting of ADRs \[[@B93],[@B94]\].

Alternative signal detection approaches
---------------------------------------

New ADR signals are often documented by only a small number of case reports, and systematic inclusion of data mining procedures in assessment of new ADR signals would probably contribute to earlier detection and quantification of serious ADR signals \[[@B95],[@B96]\]. However, data mining was not applied in the three therapeutic cases studied here. Examples of data mining are cumulative techniques, time scans and Poisson methods, proportional reporting ratios (PRRs) and Bayesian data mining \[[@B97]\]. These methods assess how much the observed reporting frequency of a given drug-event combination deviates from that expected, given statistical independence between drug and event. Methodological and practical experiences with data mining in signal detection are limited \[[@B97],[@B98]\].

Strengths and limitations of the study
--------------------------------------

The objective of this review was to analyse which information signal detection approaches have produced about new ADRs in selected and published therapeutic cases, rather than to perform a systematic review of the entire body of ADR literature covering all therapeutic groups. The choice of widely different therapeutic cases and the similar results obtained across therapeutic cases make us believe that the results qualitatively reflect the general, published experience on ADRs based on signal detection approaches. Findings across therapeutic cases were similar with respect to methodological approaches and time of publication, despite the fact that ADRs differed in nature and affected different organs. Although antibiotics have been marketed since the 1940s, it was not possible to search for literature before the mid-1960s due to the limitations of current databases. Lack of consistency in reporting ADRs, different methodologies used in the studies and their impact on the results are difficult to evaluate in this review.

Conclusion
==========

Although the medicines were launched in different decades, approaches to the ADR studies were similar for all three therapeutic cases: antibiotics, NSAIDs and SSRIs. Descriptive as well as analytical designs were applied. Despite the fact that the analytical studies rank higher in the evidence hierarchy, only the descriptive case reports/spontaneous reports provided information about new and previously undetected ADRs. This review underscores the importance of systems for spontaneous reporting of ADRs. Therefore, spontaneous reporting should be encouraged further and the information in ADR databases should continuously be subjected to systematic analysis.
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